CRISPR Therapeutics
CRSP
CRSP
380 hedge funds and large institutions have $2.54B invested in CRISPR Therapeutics in 2023 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 102 increasing their positions, 120 reducing their positions, and 57 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
4% less funds holding
Funds holding: 396 → 380 (-16)
15% less repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 120
16% less first-time investments, than exits
New positions opened: 48 | Existing positions closed: 57
Holders
380
Holding in Top 10
3
Calls
$79.7M
Puts
$71.8M
Top Buyers
| 1 | +$30.3M | |
| 2 | +$30.3M | |
| 3 | +$9.85M | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$9.72M |
| 5 |
Two Sigma Investments
New York
|
+$7.88M |
Top Sellers
| 1 | -$13.2M | |
| 2 | -$11.7M | |
| 3 | -$10M | |
| 4 |
AC
Armistice Capital
New York
|
-$9.59M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$9.21M |